On September 21, 2017 Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) reported that it has been included in the Dow Jones Sustainability Asia/Pacific Index (DJSI Asia/Pacific), the Asia Pacific subset of the 2017 Dow Jones Sustainability Indices (DJSI), a representative benchmark for socially responsible investing (SRI)* (Press release, Dainippon Sumitomo Pharma, SEP 21, 2017, View Source [SID1234520583]). This is a first for the company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The DJSI are SRI indices developed through collaboration between S&P Dow Jones Indices(U.S.) and RobecoSAM(Switzerland). Sustainability of corporate activity is evaluated on the basis of three dimensions —economic, environmental, and social— with recognition given to outstanding companies.
Sumitomo Dainippon Pharma’s selection for inclusion in the 2017 DJSI was based on its high evaluation results with respect to criteria including Product Quality and Recall Management, Innovation Management, and Health Outcome Contribution. The Company is already a component of global SRI indices FTSE4Good Index Series (for 15 consecutive years), and Morgan Stanley Capital International (MSCI) Global Sustainability Indexes (for six consecutive years). Moreover, starting from the current fiscal year, the Company is included in Morningstar Socially Responsible Investment Index(MS-SRI), an SRI index of Japanese listed companies.
Our responsibility to society, encapsulated in our Corporate Mission, is "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," and we define the implementation of this mission as our "CSR management." We remain committed to the practice of CSR management and the sustainable enhancement of corporate value.
*: Socially Responsible Investment (SRI)
Investment strategy whereby potential investors take into account assessments of a company’s policies and actions in respect of environmental issues, corporate social responsibility and governance, in addition to analysis of financial performance.